MyFinsight
Home
Blog
About
Contact
Download
Download image
Tyvaso DPI
$1,292,500K
Nebulized Tyvaso
$585,700K
Remodulin
$526,800K
Orenitram
$496,900K
Unituxin
$226,800K
Adcirca
$30,000K
Product And Service
Other
$24,000K
Total revenues
$3,182,700K
Interest income
$192,000K
Other income
(expense), net
$48,900K
Operating income
$1,492,500K
Total other income,
net
$221,400K
Total operating
expenses
$1,690,200K
Interest expense
$19,500K
Income before income
taxes
$1,713,900K
Selling, general, and
administrative
$755,800K
Research and development
$550,000K
Cost of sales
$384,400K
Net income
$1,334,700K
Income tax expense
$379,200K
Back
Back
Income Statement
source: myfinsight.com
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)